4.3 Article

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Dermatology

Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7

Jonathan I. Silverberg et al.

Summary: Baricitinib combined with topical corticosteroids (TCS) has shown sustained efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) over a 68-week period.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Allergy

Specific T cells targeting Staphylococcus aureus fibronectin-binding protein 1 induce a type 2/type 1 inflammatory response in sensitized atopic dermatitis patients

Ahmed K. Farag et al.

Summary: This study identified FBP1-specific T cells in AD patients, which predominantly secreted type 2 cytokines IL-13 and IL-4. These findings suggest that FBP1 may induce a pro-inflammatory T helper cell response with increased Th2 levels, contributing to allergic inflammation in sensitized AD patients.

ALLERGY (2022)

Article Dermatology

Inappropriate systemic therapy in severe atopic dermatitis-severe long-term damage

F. Abeck et al.

Summary: Recent advancements in the approval of new systemic drugs such as biologicals and Janus kinase inhibitors have fundamentally improved treatment options for severe cases of atopic dermatitis. However, there are still cases where modern treatment options are not considered, requiring more guideline-based therapy and interdisciplinary cooperation.

DERMATOLOGIE (2022)

Article Dermatology

The Eczema Area and Severity Index-A Practical Guide

Jon M. Hanifin et al.

Summary: This review serves as the definitive guide for the Eczema Area and Severity Index (EASI), addressing commonly asked questions and helping readers to effectively utilize and interpret this tool.

DERMATITIS (2022)

Review Allergy

New treatments in atopic dermatitis

Neha Puar et al.

Summary: The review discusses the efficacy and safety of novel and emerging topical and systemic therapeutic agents for atopic dermatitis, highlighting the new drugs currently in clinical trials and future directions. It emphasizes the need to develop new targeted therapies for effective management of atopic dermatitis and outlines future research focus areas in developing predictive models for personalized management options.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Article Dermatology

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

T. Bieber et al.

Summary: This study reports pooled safety data for baricitinib in patients with moderate-to-severe AD, confirming the established safety profile of baricitinib in this population.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Article Dermatology

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials

Brett King et al.

Summary: This study evaluated the safety of baricitinib 2 mg in treating moderate-to-severe AD, and found that treatment-emergent adverse events were higher with the drug compared to placebo, but serious adverse events were low and similar between the two groups. The integrated analysis confirmed the established safety profile of baricitinib 2 mg in patients with AD, but longer exposure to treatment is needed to assess the risks of malignancies and major adverse cardiovascular events.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Article Dermatology

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders An Extension Study of 2 Randomized Clinical Trials

Jonathan I. Silverberg et al.

Summary: Baricitinib, a selective Janus kinase inhibitor, showed sustained long-term efficacy for patients with moderate to severe atopic dermatitis through 52 weeks of continuous therapy, improving clinical assessment scores and itch symptoms.

JAMA DERMATOLOGY (2021)

Article Dermatology

Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7

Jacob P. Thyssen et al.

Summary: This study analyzed the effect of baricitinib on skin pain in atopic dermatitis, showing that baricitinib can improve skin pain severity at an early stage and maintain its effectiveness at 16 weeks.

DERMATOLOGY AND THERAPY (2021)

Review Immunology

Itch: A Paradigm of Neuroimmune Crosstalk

Fang Wang et al.

IMMUNITY (2020)

Review Allergy

Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity

Takashi Nomura et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Review Allergy

The Role of Environmental Exposures in Atopic Dermatitis

Shanthi Narla et al.

CURRENT ALLERGY AND ASTHMA REPORTS (2020)

Article Dermatology

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

A. Wollenberg et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Review Dermatology

Genetics in Atopic Dermatitis: Historical Perspective and Future Prospects

Sara J. Brown et al.

ACTA DERMATO-VENEREOLOGICA (2020)

Review Dermatology

Disease Mechanisms in Atopic Dermatitis: A Review of Aetiological Factors

Jacob P. Thyssen et al.

ACTA DERMATO-VENEREOLOGICA (2020)

Article Allergy

Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation

Riana D. Sanyal et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)

Review Allergy

Comorbidities and the impact of atopic dermatitis

Jonathan I. Silverberg

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)

Article Health Care Sciences & Services

Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis

Louise Newton et al.

JOURNAL OF PATIENT-REPORTED OUTCOMES (2019)

Article Dermatology

Epidemiology of adult atopic dermatitis

Ryan Sacotte et al.

CLINICS IN DERMATOLOGY (2018)

Article Dermatology

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I

A. Wollenberg et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

Article Dermatology

Atopic dermatitis: pathogenesis

Emma Guttman-Yassky et al.

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2017)

Article Allergy

Burden of skin pain in atopic dermatitis

Paras P. Vakharia et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2017)

Letter Dermatology

Impact of disease severity on sleep quality in Japanese patients with atopic dermatitis

Chizuko Yano et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2013)

Article Dermatology

Relationship between itch and psychological status of patients with atopic dermatitis

D. Chrostowska-Plak et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)

Article Dermatology

Itch characteristics in atopic dermatitis: results of a web-based questionnaire

A. Dawn et al.

BRITISH JOURNAL OF DERMATOLOGY (2009)

Article Dermatology

Does age or gender influence quality of life in children with atopic dermatitis?

K. L. E. Hon et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2008)

Article Dermatology

Disease severity, scratching, and sleep quality in patients with atopic dermatitis

Bruce G. Bender et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)